RxDoctor Payments Data

Birendra Trivedi, MD

Neurology · Massapequa, NYNPI 1992750244

Payments from drug & device makers

$14,011in general payments, 2019–2025

Across 664 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • AstraZeneca$1K
  • Eisai Inc.$986
  • plus $7K from 52 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$13,72298%
  • Education$2692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.63$1,313
AbbVie(2 entities)60$1,218
Teva Pharmaceuticals USA, Inc.32$1,053
Biogen54$1,038
AstraZeneca(2 entities)42$1,032
Eisai Inc.54$986
Novartis38$726
Lundbeck LLC31$573
Argenx US, Inc.20$537
Neurelis, Inc.20$480
SK Life Science, Inc.20$461
Acadia Pharmaceuticals Inc24$405
Lilly USA, LLC16$320
Supernus Pharmaceuticals, Inc.17$292
Pfizer12$269
Otsuka America Pharmaceutical, Inc.11$242
Biohaven Pharmaceutical Holding Company Ltd.10$228
EMD Serono, Inc.13$213
Neurocrine Biosciences, Inc.8$193
Arbor Pharmaceuticals, Inc.11$185
Amneal Pharmaceuticals LLC7$171
Harmony Biosciences LLC6$151
Sumitomo Pharma America, Inc.7$150
Sunovion Pharmaceuticals Inc.9$132
Corium, LLC7$131
Catalyst Pharmaceuticals, Inc.6$115
Medtronic3$108
Almatica Pharma LLC5$104
Grifols USA, LLC3$87
Impel Pharmaceuticals Inc.4$86
Amgen(2 entities)4$74
Sanofi3$68
Johnson & Johnson2$63
Scilex Pharmaceuticals Inc.3$61
Biohaven Pharmaceuticals, Inc.3$61
Jazz Pharmaceuticals Inc.2$58
Boehringer Ingelheim3$57
Xeris Pharmaceuticals, Inc.3$49
Takeda Pharmaceuticals U.S.A., Inc.2$48
Bristol Myers Squibb2$46
Amylyx Pharmaceuticals, Inc.2$44
Tanabe Pharma America, Inc.2$39
Avion Pharmaceuticals2$37
Acorda Therapeutics, Inc2$36
Strongbridge US Inc.2$26
Philips North America LLC1$24
Axsome Therapeutics, Inc.1$24
GE HealthCare2$23
Vanda Pharmaceuticals Inc.1$23
Genentech USA, Inc.1$22
Tris Pharma Inc1$21
Mallinckrodt Hospital Products Inc.1$21
Abbott1$20
E.r. Squibb & Sons, L.L.C.1$17
Zogenix Inc.1$14
Vertical Pharmaceuticals, LLC1$13
Orthofix Medical, Inc.1$12
Greenwich Biosciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,011 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$441,388
Medicare patients
1,014
Services billed
3,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant18$29,845
RexultiBrexpiprazole15$22,542
Nurtec OdtRimegepant Sulfate11$22,436
NamzaricMemantine Hcl/Donepezil Hcl14$20,607
XcopriCenobamate12$12,852
Lacosamide99$10,146
Pregabalin314$9,980
Memantine Hcl190$6,595
Levetiracetam237$6,034
Felbamate13$5,552
Memantine Hcl ErMemantine Hcl70$4,993
QelbreeViloxazine Hcl11$3,802
Aspirin-Dipyridamole ErAspirin/Dipyridamole15$3,705
Lamotrigine ErLamotrigine15$3,496
CarbatrolCarbamazepine21$3,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Namzaric$1,218$50,45332 claims
Otsuka America Pharmaceutical, Inc.Rexulti$242$22,54215 claims
PfizerNurtec Odt$269$22,43611 claims
SK Life Science, Inc.Xcopri$461$12,85212 claims
Supernus Pharmaceuticals, Inc.Qelbree$292$3,80211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →